SL
RCUS icon

Salomon & Ludwin’s Arcus Biosciences RCUS Stock Holding History

Salomon & Ludwin’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.2K Buy
1,055
+257
+32% +$5.55K ﹤0.01% 951
2025
Q4 		$17.4K Hold
798
– – ﹤0.01% 1014
2025
Q3 		$10.7K Buy
+798
New +$8.3K ﹤0.01% 1258

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Salomon & Ludwin's RCUS Position: Q1 2026 in Review

Salomon & Ludwin increased its Arcus Biosciences (RCUS) stake by 32% in Q1 2026, buying an estimated $5.55K and bringing the position to 1,055 shares worth $24.2K. The position accounts for ﹤0.01% of the portfolio, ranked #951.

Salomon & Ludwin first reported a position in RCUS in Q3 2025 and has held it in 3 quarters since. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Salomon & Ludwin held 1,055 shares of Arcus Biosciences worth $24.2K as of Q1 2026.
  • Salomon & Ludwin bought 257 Arcus Biosciences shares in Q1 2026, an estimated $5.55K.
  • Arcus Biosciences made up ﹤0.01% of Salomon & Ludwin's portfolio in Q1 2026, its #951 holding.
  • Salomon & Ludwin first reported a position in Arcus Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Salomon & Ludwin's 13F filing for Q1 2026, filed 11 May 2026.